Sun Pharma, announced its association with gold medalist snowboarder and 2015 ESPY Best Female Action Sports Athlete Kelly Clark. Through this association, Kelly Clark will share her life experience of living with severe recalcitrant nodular acne and her recent treatment with Absorica (isotretinoin) capsules.
The engagement with Kelly Clark is part of Sun Pharma’s efforts to introduce a patient education program “Leave Acne Behind” and develop a variety of patient help resources and tools. Absorica (isotretinoin) capsules are indicated for the treatment of severe recalcitrant nodular acne in patients 12 years of age and older.
This is the most severe form of acne for patients who are unresponsive to conventional therapy1including antibiotics. Kelly Clark has struggled with this condition since her early teens. She recently underwent successful treatment with Absorica.
Commenting on her treatment with Absorica, Kelly Clark said, “Living with severe recalcitrant nodular acne was challenging, I never knew when I would have a flare-up,” explained Kelly. “Often it would be the day of an important competition or television interview and trying to conceal it was frustrating,” she added. “I was relieved to learn about Absorica, not only because it offered me hope, but as a competitive athlete, it would not compromise my training diet. I can’t be eating the high fat meals that would have been necessary with otherisotretinoin treatments.”
Commenting on Sun Pharma’s association with Kelly Clark, Dr. Ashish Anvekar, Vice President, Brand Division -USA said, “We’re very pleased that Kelly had such a positive treatment experience with Absorica. We hope that her successful journey inspires others with severe recalcitrant nodular acne to speak to their dermatologist about treatment options.”
Isotretinoin is the standard treatment for the diagnosis of severe recalcitrant nodular acne. Absorica (isotretinoin) 10, 20, 25*, 30, 35*, 40 mg, launched in 2012, has become the most prescribed branded oral isotretinoin in the U.S., as per a recent sample survey conducted with 300 Dermatologists and other oral isotretinoin writers3
The product is licensed to Ranbaxy Laboratories Inc. (a SUN PHARMA company) by Cipher Pharmaceuticals, Inc.
Click here to be taken to the original source of this email.